HCA vs. GSK, GILD, REGN, MCK, BMY, ZTS, BSX, BDX, CI, and VRTX
Should you be buying HCA Healthcare stock or one of its competitors? The main competitors of HCA Healthcare include GSK (GSK), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), McKesson (MCK), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Boston Scientific (BSX), Becton, Dickinson and Company (BDX), The Cigna Group (CI), and Vertex Pharmaceuticals (VRTX). These companies are all part of the "medical" sector.
GSK (NYSE:GSK) and HCA Healthcare (NYSE:HCA) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their community ranking, risk, valuation, analyst recommendations, institutional ownership, profitability, media sentiment, dividends and earnings.
15.7% of GSK shares are held by institutional investors. Comparatively, 62.7% of HCA Healthcare shares are held by institutional investors. 10.0% of GSK shares are held by insiders. Comparatively, 1.6% of HCA Healthcare shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
HCA Healthcare has a consensus price target of $310.88, suggesting a potential upside of 1.39%. Given GSK's stronger consensus rating and higher possible upside, analysts plainly believe HCA Healthcare is more favorable than GSK.
GSK pays an annual dividend of $1.59 per share and has a dividend yield of 3.9%. HCA Healthcare pays an annual dividend of $2.64 per share and has a dividend yield of 0.9%. GSK pays out 52.8% of its earnings in the form of a dividend. HCA Healthcare pays out 13.9% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GSK has raised its dividend for 1 consecutive years and HCA Healthcare has raised its dividend for 4 consecutive years.
GSK has a net margin of 16.24% compared to GSK's net margin of 8.07%. GSK's return on equity of 996.30% beat HCA Healthcare's return on equity.
GSK has a beta of 0.64, meaning that its stock price is 36% less volatile than the S&P 500. Comparatively, HCA Healthcare has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.
In the previous week, HCA Healthcare had 23 more articles in the media than GSK. MarketBeat recorded 38 mentions for HCA Healthcare and 15 mentions for GSK. GSK's average media sentiment score of 0.65 beat HCA Healthcare's score of 0.17 indicating that HCA Healthcare is being referred to more favorably in the news media.
GSK has higher earnings, but lower revenue than HCA Healthcare. GSK is trading at a lower price-to-earnings ratio than HCA Healthcare, indicating that it is currently the more affordable of the two stocks.
HCA Healthcare received 380 more outperform votes than GSK when rated by MarketBeat users. Likewise, 77.22% of users gave HCA Healthcare an outperform vote while only 57.04% of users gave GSK an outperform vote.
Summary
HCA Healthcare beats GSK on 15 of the 21 factors compared between the two stocks.
Get HCA Healthcare News Delivered to You Automatically
Sign up to receive the latest news and ratings for HCA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HCA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
HCA Healthcare Competitors List
Related Companies and Tools
